TNF and type 2 diabetes mellitus: While current guidelines for treating PDN only use neuropathic pain regimens [52], our results suggest that a combination of both neuropathic and anti-inflammatory therapies that target COX2, iNOS, and TNF-α will improve the current standard treatment for PDN of type 2 diabetes.